A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome

Clinical Cancer Research

Volumn 17, Issue 7, 2011, Pages 2006-2013

  Caronia, Daniela ^a   Martin, Miguel ^b   Sastre, Javier ^c   De La Torre, Julio ^c   García Sáenz, José Angel ^c   Alonso, Maria R ^a   Moreno, Leticia T ^a   Pita, Guillermo ^a   Díaz Rubio, Eduardo ^c   Benítez, Javier ^a   González Neira, Anna ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; MESSENGER RNA; TRANSCRIPTION FACTOR E2F;

ADULT; AGED; ALLELE; ARTICLE; BINDING SITE; BONE MARROW SUPPRESSION; BREAST CANCER; CARBOXYESTERASE 2 GENE; COLORECTAL CANCER; CYTIDINE DEAMINASE GENE; DIHYDROPYRIMIDINE DEHYDROGENASE GENE; DISEASE SEVERITY; DNA POLYMORPHISM; DRUG METABOLISM; EPSTEIN BARR VIRUS; FEMALE; GENE; GENE DELETION; GENE EXPRESSION; GENE INSERTION; GENE LINKAGE DISEQUILIBRIUM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HAND FOOT SYNDROME; HUMAN; HUMAN CELL; LYMPHOBLASTOID CELL; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; PHARMACOGENETICS; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION; THYMIDINE PHOSPHORYLASE GENE; THYMIDYLATE SYNTHASE GENE;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; BASE SEQUENCE; BINDING SITES; BREAST NEOPLASMS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; CYTIDINE DEAMINASE; DEOXYCYTIDINE; E2F TRANSCRIPTION FACTORS; ERYTHEMA; FEMALE; FLUOROURACIL; FOOT DERMATOSES; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HAND DERMATOSES; HAPLOTYPES; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PAIN; POLYMORPHISM, SINGLE NUCLEOTIDE; PRODRUGS; PROMOTER REGIONS, GENETIC; SEQUENCE ANALYSIS, DNA; SYNDROME; TRANSCRIPTION, GENETIC;

EID: 79953309898     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-1741     Document Type: Article

References (21)

1. McKendrick J, Coutsouvelis J. Capecitabine: effective oral fluoropyrimidine chemotherapy. Expert Opin Pharmacother 2005;6:1231-9. (Pubitemid 40959484)
2. Walko CM, Lindley C. Capecitabine: a review. Clin Ther 2005;27:23-44. (Pubitemid 40347299)
3. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998;34:1274-81. (Pubitemid 28342121)
4. Webster-Gandy JD, How C, Harrold K. Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre. Eur J Oncol Nurs 2007;11:238-46.
5. Nagore E, Insa A, Sanmartin O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia ("hand-foot") syndrome. Incidence, recognition and management. Am J Clin Dermatol 2000;1:225-34.
6. Ulrich CM, Bigler J, Bostick R, Fosdick L, Potter JD. Thymidylate synthase promoter polymorphism, interaction with folate intake, and risk of colorectal adenomas. Cancer Res 2002;62:3361-4. (Pubitemid 34651378)
7. van Kuilenburg AB. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 2004;40:939-50.
8. Largillier R, Etienne-Grimaldi MC, Formento JL, Ciccolini J, Nebbia JF, Ginot A, et al. Pharmacogenetics of capecitabine in advanced breast cancer patients. Clin Cancer Res 2006;12:5496-502. (Pubitemid 44497266)
9. Ribelles N, López-Siles J, Sánchez A, González E, Sánchez MJ, Carabantes F, et al. A carboxylesterase 2 gene polymorphism as predictor of capecitabine on response and time to progression. Curr Drug Metab 2008;9:336-43. (Pubitemid 351836423)
10. Fitzgerald SM, Goyal RK, Osborne WR, Roy JD, Wilson JW, Ferrell RE. Identification of functional single nucleotide polymorphism haplotypes in the cytidine deaminase promoter. Hum Genet 2006;119:276-83.
11. Sugiyama E, Kaniwa N, Kim SR, Kikura-Hanajiri R, Hasegawa R, Maekawa K, et al. Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. J Clin Oncol 2007;25:32-42. (Pubitemid 350003048)
12. Fukunaga AK, Marsh S, Murry DJ, Hurley TD, McLeod HL. Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway. Pharmacogenomics J 2004;4:307-14. (Pubitemid 39341569)
13. Gilbert JA, Salavaggione OE, Ji Y, Pelleymounter LL, Eckloff BW, Wieben ED, et al. Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. Clin Cancer Res 2006;12:1794-803.
14. Salgado J, Zabalegui N, Gil C, Monreal I, Rodriguez J, Garcia-Foncillas J. Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer. Oncol Rep 2007;17:325-8.
15. Wei X, McLeod HL, McMurrough J, Gonzalez FJ, Fernandez-Salguero P. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest 1996;98:610-5. (Pubitemid 26349163)
16. van Kuilenburg AB, Muller EW, Haasjes J, Meinsma R, Zoetekouw L, Waterham HR, et al. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency. Clin Cancer Res 2001;7:1149-53. (Pubitemid 32708664)
17. Mandola MV, Stoehlmacher J, Muller-Weeks S, Cesarone G, Yu MC, Lenz HJ, et al. A novel single nucleotide polymorphism within the 5′ tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res 2003;63:2898-904. (Pubitemid 36667162)
18. Bajetta E, Procopio G, Celio L, Gattinoni L, Della Torre S, Mariani L, et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 2005;23:2155-61. (Pubitemid 46218707)
19. Yue L, Saikawa Y, Ota K, Tanaka M, Nishimura R, Uehara T, et al. A functional single-nucleotide polymorphism in the human cytidine deaminase gene contributing to ara-C sensitivity. Pharmacogenetics 2003;13:29-38. (Pubitemid 36135684)
20. Yonemori K, Ueno H, Okusaka T, Yamamoto N, Ikeda M, Saijo N, et al. Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin. Clin Cancer Res 2005;11:2620-4. (Pubitemid 40569462)
21. Milano G, Etienne-Grimaldi MC, Mari M, Lassalle S, Formento JL, Francoual M, et al. Candidate mechanisms for capecitabine-related hand-foot syndrome. Br J Clin Pharmacol 2008;66:88-95. (Pubitemid 351822156)